introductionhuman
norovirus
primari
caus
agent
acut
gastroenter
press
public
health
burden
worldwid
current
vaccin
small
molecul
therapeut
avail
treatment
prophylaxi
noroviru
infect
improv
understand
noroviru
biolog
well
pathogen
mechan
underli
diseas
provid
impetu
rang
intens
exploratori
drug
discoveri
effort
target
viral
host
factor
area
coveredan
overview
noroviru
inhibitor
disclos
patent
literatur
clinicaltrialsgov
present
review
enrich
supplement
recent
literatur
report
expert
opinionsemin
discoveri
made
recent
year
includ
better
understand
pathobiolog
life
cycl
noroviru
identif
target
multipl
viral
host
factor
advent
replicon
system
small
anim
model
preclin
evalu
lead
compound
avail
high
resolut
xray
crystal
structur
util
structurebas
drug
design
lead
optim
campaign
collect
suggest
small
molecul
therapeut
prophylact
noroviru
infect
like
emerg
distant
futur
human
norovirus
princip
caus
nonbacteri
acut
gastroenter
worldwid
estim
norovirus
respons
million
infect
author
support
nation
institut
health
grant
number
author
relev
affili
financi
involv
organ
entiti
financi
interest
financi
conflict
subject
matter
materi
discuss
manuscript
apart
disclos
human
norovirus
grow
cell
cultur
precis
understand
life
cycl
human
noroviru
remain
elus
nevertheless
comprehens
review
current
understand
noroviru
life
cycl
publish
although
mani
aspect
noroviru
replic
await
sharper
definit
basic
step
compris
noroviru
infect
includ
initi
util
carbohydr
factor
attach
surfac
intestin
epitheli
cell
follow
receptor
bind
entri
histoblood
group
antigen
oligosaccharid
link
membran
bound
protein
lipid
present
surfac
red
blood
cell
mucos
epithelia
serv
attach
factor
receptor
noroviru
attach
entri
subsequ
uncoat
releas
viral
genom
undergo
translat
via
mediat
vpg
cellular
translat
machineri
polyprotein
coand
posttransl
cleav
noroviru
pro
format
replic
complex
follow
genom
replic
rdrp
gener
genom
subgenom
rna
use
de
novo
vpgdepend
initi
mechan
replic
genom
packag
capsid
virion
assembl
exit
epidem
gastroenter
mostli
occur
hospit
nurs
home
school
militari
barrack
restaur
infect
present
form
multipl
symptom
includ
diarrhea
vomit
nausea
abdomin
pain
infect
incapacit
selflimit
healthi
adult
last
day
howev
viral
shed
continu
much
longer
even
disappear
symptom
sourc
contamin
infect
state
earlier
diseas
lifethreaten
children
elderli
immunocompromis
patient
need
better
understand
mechan
norovirus
infect
gastrointestin
tract
previou
biopsi
result
well
studi
gnotobiot
pig
calv
infect
human
noroviru
suggest
human
noroviru
target
intestin
epitheli
cell
recent
studi
suggest
norovirus
infect
macrophag
dendrit
cell
b
cell
howev
clear
human
noroviru
target
cell
natur
host
structur
studi
shown
noroviru
capsid
icosahedr
geometri
compos
organ
dimer
major
capsid
protein
compris
two
major
domain
interiorform
shell
domain
exterior
protrud
p
domain
tether
flexibl
hing
p
domain
divid
two
subdomain
latter
locat
outermost
surfac
capsid
least
conserv
region
among
noroviru
strain
serv
primari
site
interact
individu
oligosaccharid
residu
hbga
receptor
mention
earlier
human
norovirus
recogn
histoblood
group
antigen
hbga
bind
ligand
recognit
histoblood
group
antigen
norovirus
known
play
pivot
role
viral
infect
tropism
structur
electrospray
ioniz
mass
spectrometri
esim
studi
illumin
interact
hbga
norovirus
importantli
shown
recent
use
catchandreleas
electron
spray
ioniz
mass
spectrometri
caresim
assay
human
norovirus
recogn
bind
sialic
acidcontain
glycosphingolipid
compar
affin
hbga
oligosaccharid
receptor
hbgabind
interfac
conserv
human
norovirus
consequ
agent
block
hbga
bind
site
may
abrog
viral
infect
noroviru
strain
toward
end
caresim
assay
use
screen
carbohydr
librari
identifi
noroviru
ligand
potenti
inhibitor
relat
effort
involv
screen
smallmolecul
librari
use
viru
like
particl
vlp
result
identif
sever
bind
blocker
advanc
area
begin
lay
solid
foundat
eventu
develop
viru
entri
inhibitor
computeraid
drug
design
approach
involv
construct
valid
comput
model
target
protein
base
crystal
structur
known
function
hbga
bind
site
b
virtual
high
throughput
screen
compound
librari
identifi
hit
c
subsequ
biochem
valid
identifi
inhibitor
result
identif
sever
compound
block
bind
noroviru
hbga
high
affin
display
low
cytotox
figur
structur
identifi
compound
share
common
cyclopenta
phenanthren
scaffold
use
launch
pad
conduct
structureact
relationship
studi
follow
translat
viral
genom
viral
polyprotein
cleav
cystein
proteas
pro
prototyp
catalyt
triad
strong
prefer
gln
residu
gener
structur
nonstructur
protein
central
role
pro
play
viru
replic
enzym
appeal
target
design
norovirusspecif
antivir
drug
consequ
pro
focu
intens
studi
use
robust
fretbas
assay
cellbas
replicon
system
array
inhibitor
proteas
display
antinoroviru
activ
report
includ
peptidyl
transit
ts
inhibitor
aldehyd
latent
ts
inhibitor
ts
mimic
vide
infra
avail
sever
high
resolut
xray
crystal
structur
bound
ligand
invalu
use
structureguid
approach
design
inhibitor
enzym
aldehyd
shown
highli
effect
inhibitor
noroviru
pro
noroviru
cellbas
replicon
cell
peptidyl
inhibitor
pro
demonstr
efficaci
murin
model
noroviru
infect
current
preclin
develop
synthesi
peptidyl
deriv
gener
structur
figur
readili
accomplish
illustr
figur
repres
result
summar
tabl
correspond
bisulfit
aldehyd
adduct
also
found
effect
latent
form
aldehyd
function
condit
use
revert
aldehyd
actual
inhibitori
speci
demonstr
xray
crystallographi
peptidyl
transit
state
mimic
also
effect
inhibitor
noroviru
pro
noroviru
cellbas
replicon
cell
tabl
final
note
substrat
specif
proteas
virus
picornaviruslik
superclust
similar
tabl
consequ
principl
possibl
design
broad
spectrum
inhibitor
addit
ts
inhibitor
rupintrivir
peptidyl
inhibitor
ester
michael
acceptor
origin
develop
enteroviru
shown
effect
norovirus
effici
clear
human
cell
norwalk
replicon
antinoroviru
activ
extend
murin
noroviru
addit
antivir
effect
observ
rupintrivir
use
combin
polymeras
inhibitor
importantli
crossgenotyp
antinoroviru
activ
display
rupintrivir
suggest
like
effect
clinic
relev
gi
gii
norovirus
figur
synthes
shown
display
broadspectrum
activ
virus
belong
picornaviruslik
superclust
includ
import
human
anim
pathogen
norovirus
enterovirus
coronavirus
rhinovirus
other
repres
synthesi
triazolebas
macrocycl
aldehyd
shown
figur
conform
constrain
macrocycl
found
display
cellular
permeabl
anticip
possess
improv
stabil
oral
bioavail
numer
polymeras
inhibitor
includ
nucleosid
analog
prodrug
variant
approv
antivir
agent
array
virus
includ
hepat
c
viru
hcv
hiv
hbv
virus
mechan
action
nucleosid
analog
involv
convers
inact
nucleosid
phosphat
diphosph
form
actual
inhibitori
speci
consequ
noroviru
rdrp
attract
target
wellsuit
develop
norovirusspecif
therapeut
due
vital
role
rdrp
play
noroviru
replic
cycl
b
avail
high
resolut
xray
crystal
structur
free
ligandbound
enzym
complex
c
absenc
human
homolog
diminish
likelihood
offtarget
effect
sever
novel
nucleosid
inhibitor
shown
inhibit
noroviru
via
inhibit
rdrp
figur
repres
synthes
inhibitor
variant
illustr
figur
drug
repurpos
reposit
name
strategi
appli
establish
drug
new
indic
result
identif
nucleosid
signific
antinoroviru
activ
instanc
nucleosid
analog
found
complet
block
transmiss
noroviru
afford
protect
norovirusinduc
diarrhea
mortal
mous
model
may
suitabl
use
prophylact
figur
moreov
pyrazin
carboxamid
antivir
agent
favipiravir
shown
inhibit
noroviru
replic
mode
action
well
understood
inhibitor
noroviru
rdrp
collect
aforement
studi
strongli
suggest
futur
armamentarium
antinoroviru
therapeut
like
includ
one
nucleosid
analog
use
individu
combin
proteas
inhibitor
lower
potenti
emerg
resist
associ
target
host
factor
provid
impetu
explor
host
factor
potenti
therapeut
target
includ
interferon
ifn
deubiquitinas
cholesterol
pathway
inhibitor
studi
earli
stage
rapid
advanc
noroviru
pathobiolog
like
identifi
addit
host
factor
worthi
investig
sever
studi
describ
inhibit
norovirus
low
molecular
weight
compound
via
unknown
mechan
report
includ
cyclic
acycl
sulfamid
structur
variant
pyranobenzopyron
chromon
figur
current
compound
evalu
clinic
trial
antinoroviru
therapeut
nitazoxanid
figur
broad
spectrum
antivir
agent
multipl
virus
includ
hcv
influenza
viru
shown
efficaci
noroviru
infect
mechan
well
understood
limit
number
compound
capabl
inhibit
noroviru
disclos
thu
far
patent
literatur
includ
peptidyl
macrocycl
transit
state
inhibitor
well
transit
state
mimic
noroviru
proteas
nucleosid
nonnucleosid
inhibitor
rna
depend
rna
polymeras
steroid
deriv
capabl
block
bind
norovirus
hbga
receptor
studi
earli
stage
develop
preclin
studi
need
carri
rigor
assess
class
compound
made
despit
fact
noroviru
infect
exact
heavi
toll
term
morbid
econom
burden
worldwid
effect
small
molecul
therapeut
prophylact
control
diseas
current
avail
howev
increas
awar
norovirus
public
health
like
acceler
drug
discoveri
effort
area
advers
impact
lack
cell
cultur
model
complet
human
noroviru
replic
mitig
avail
viruslik
particl
bind
assay
noroviru
replicon
harbor
cell
mnv
vitro
vivo
model
provid
excel
tool
drug
discoveri
effort
signific
advanc
made
field
recent
year
greatli
illumin
understand
noroviru
biolog
pathogenesi
mani
facet
diseas
await
better
understand
viral
host
factor
identifi
thu
far
could
serv
potenti
druggabl
target
includ
viral
target
entri
blocker
pro
rdrp
inhibitor
keen
interest
use
new
nucleosid
repurpos
nucleosid
inhibitor
rdrp
inhibitor
well
pro
inhibitor
studi
earli
preclin
stage
high
throughput
screen
librari
use
enzym
assay
noroviru
replicon
harbor
cell
system
like
result
identif
druglik
hit
amen
optim
advanc
along
develop
pipelin
obstacl
imped
progress
field
gener
well
noroviru
outbreak
control
particular
includ
lack
highli
sensit
specif
low
cost
diagnost
test
optim
use
earli
detect
noroviru
infect
b
effect
safe
decontamin
agent
c
effect
vaccin
cell
cultur
model
e
anim
model
recapitul
aspect
human
noroviru
infect
f
better
understand
noroviru
infect
howev
despit
obstacl
great
stride
made
understand
noroviru
biolog
pathobiolog
buttress
ongo
research
endeavor
ultim
lead
introduct
norovirusspecif
therapeut
clinic
clearli
preval
impact
noroviru
infect
warrant
develop
norovirusspecif
drug
respect
diagnosi
surveil
control
noroviru
outbreak
variou
antivir
composit
report
patent
literatur
linear
branch
alkyl
acid
deriv
sulfon
surfact
ethanol
isopropanol
shown
inactiv
nonenvelop
virus
norovirus
composit
suitabl
provid
rapid
antimicrobi
activ
norovirus
use
topic
skin
applic
hand
sanit
erad
noroviru
contamin
hard
surfac
current
use
agent
chlorin
bleach
iodin
prepar
other
provid
partial
protect
noroviru
infect
antinoroviru
disinfect
composit
compris
persimmon
extract
variou
addit
alcohol
vitamin
c
surfact
disclos
recent
interestingli
presenc
citric
acid
result
synergist
antinoroviru
effect
medicin
use
persimmon
juic
known
chines
japanes
folk
medicin
long
time
effect
may
aris
presenc
tannin
final
level
resourc
devot
research
aim
combat
norovirus
current
reflect
sever
impact
noroviru
infect
worldwid
clearli
evid
neartot
absenc
potenti
drug
candid
current
evalu
clinic
trial
undergo
advanc
preclin
evalu
unmet
need
effect
treatment
coupl
continu
studi
describ
burden
diseas
differ
target
popul
highlight
impact
public
health
system
doubt
greatli
acceler
research
effort
area
exampl
noroviru
entri
inhibitor
identifi
bind
capsid
p
protein
hbga
antinoroviru
compound
unknown
target
ec
valu
determin
nv
replicon
harbor
cell
activ
repres
dipeptidyl
inhibitor
aldehyd
bisulfit
adduct
tabl
substrat
specif
proteas
virus
picornaviruslik
superclust
viral
proteas
